The late onset of cancer symptoms can cause a significant delay in diagnosis, impacting patients’ prognosis and quality of life, thus prompting a need for alternative screening and detection methods. Neoplastic processes cause distinct and immediate changes to the body’s metabolism, creating unique patterns in the volatile organic compounds (VOCs) produced and released through exhaled breath. For this reason, VOC profiles have emerged as diagnostic indicators for several types of malignancies, facilitating early cancer detection. Both non-invasive and accessible, the analysis of breath VOCs for cancer screening and detection has gained recognition as a new frontier in cancer diagnostics.

Cardiovascular events are a leading cause of morbidity and mortality in patients undergoing noncardiac surgery. Inadequate postoperative monitoring is a major factor contributing to postoperative complications. In response to the Covid-19 pandemic, virtual care was widely implemented in Canada to facilitate post-operative patient care. Virtual postoperative care has been shown to be safe and improve postoperative outcomes. As such, postoperative virtual care should be integrated into routine practice beyond the Covid-19 pandemic. Implementation of postoperative virtual care into the Canadian healthcare system will require consideration of key issues pertaining to data security, digital literacy, and technological infrastructure, as well as the development of a national framework for data sharing and collaboration.

The growing repertoire of approved immune-checkpoint inhibitors and targeted therapy has revolutionized the adjuvant treatment of melanoma. While the treatment of primary cutaneous melanoma remains wide local excision (WLE), the management of regional lymph nodes continues to evolve in light of practice-changing clinical trials and dramatically improved adjuvant therapy. With large multicenter studies reporting no benefit in overall survival for completion lymph node dissection (CLND) after a positive sentinel node biopsy (SLNB), controversy remains regarding patient selection and clinical decision-making. This review explores the evolution of the SLNB in cutaneous melanoma in the context of a rapidly changing adjuvant treatment landscape, summarizing the key clinical trials which shaped current practice guidelines.